Your browser is no longer supported. Please, upgrade your browser.
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E21.51 EPS (ttm)12.47 Insider Own0.10% Shs Outstand149.70M Perf Week-5.85%
Market Cap40.54B Forward P/E13.14 EPS next Y20.40 Insider Trans-6.85% Shs Float146.50M Perf Month-10.17%
Income1.92B PEG- EPS next Q4.12 Inst Own86.60% Short Float1.70% Perf Quarter-16.98%
Sales11.70B P/S3.47 EPS this Y-21.10% Inst Trans0.18% Short Ratio2.58 Perf Half Y-0.64%
Book/sh71.82 P/B3.73 EPS next Y9.51% ROA7.80% Target Price417.70 Perf Year-4.24%
Cash/sh20.18 P/C13.29 EPS next 5Y-7.07% ROE17.90% 52W Range223.25 - 468.55 Perf YTD9.50%
Dividend- P/FCF15.32 EPS past 5Y10.10% ROI19.60% 52W High-42.77% Beta0.46
Dividend %- Quick Ratio1.80 Sales past 5Y4.50% Gross Margin83.90% 52W Low20.10% ATR6.57
Employees9100 Current Ratio2.10 Sales Q/Q-24.60% Oper. Margin18.90% RSI (14)23.90 Volatility2.42% 2.21%
OptionableYes Debt/Eq0.00 EPS Q/Q-68.80% Profit Margin16.40% Rel Volume1.85 Prev Close269.73
ShortableYes LT Debt/Eq0.68 EarningsOct 20 BMO Payout0.00% Avg Volume964.69K Price268.13
Recom2.30 SMA20-5.91% SMA50-13.92% SMA200-10.48% Volume1,780,471 Change-0.59%
Sep-23-21Initiated Needham Buy $400
Jun-18-21Upgrade Piper Sandler Neutral → Overweight $384 → $450
Jun-14-21Reiterated Truist Buy $458 → $647
Jun-11-21Upgrade Bernstein Mkt Perform → Outperform $500
Jun-10-21Upgrade UBS Neutral → Buy
Jun-08-21Upgrade William Blair Mkt Perform → Outperform
Jun-08-21Upgrade Robert W. Baird Underperform → Neutral $216 → $382
Jun-08-21Upgrade Citigroup Sell → Neutral $200 → $440
Jun-08-21Upgrade Atlantic Equities Underweight → Neutral $415
Jun-08-21Reiterated Stifel Buy $346 → $446
Jun-08-21Reiterated RBC Capital Mkts Sector Perform $259 → $400
Jun-08-21Reiterated Morgan Stanley Overweight $343 → $455
Jun-08-21Reiterated Jefferies Buy $450 → $500
Jun-08-21Reiterated H.C. Wainwright Buy $305 → $452
Jun-08-21Reiterated Barclays Equal Weight $265 → $395
Jun-07-21Upgrade Raymond James Underperform → Mkt Perform
Jun-07-21Upgrade Cowen Market Perform → Outperform $225 → $450
Jun-07-21Upgrade BofA Securities Underperform → Neutral $235 → $400
Feb-05-21Downgrade DZ Bank Buy → Hold $264
Jan-29-21Upgrade Stifel Hold → Buy $258 → $358
Oct-19-21 06:30AM  
Oct-18-21 04:07PM  
01:01PM  
11:55AM  
11:27AM  
11:08AM  
09:00AM  
08:09AM  
07:07AM  
02:15AM  
Oct-17-21 04:20PM  
04:20PM  
Oct-15-21 09:34AM  
05:55AM  
Oct-14-21 04:06PM  
Oct-13-21 03:01PM  
11:01AM  
06:05AM  
06:02AM  
06:00AM  
Oct-12-21 09:10AM  
Oct-10-21 06:30AM  
Oct-09-21 02:30PM  
Oct-08-21 02:31PM  
07:40AM  
06:31AM  
Oct-07-21 06:02AM  
Oct-05-21 10:01AM  
06:15AM  
Oct-01-21 05:50PM  
10:55AM  
Sep-30-21 12:02PM  
Sep-29-21 02:24PM  
10:47AM  
06:43AM  
Sep-28-21 10:14AM  
10:14AM  
09:19AM  
06:45AM  
Sep-27-21 07:31PM  
07:30PM  
Sep-24-21 11:47AM  
Sep-23-21 05:04PM  
04:15PM  
09:03AM  
04:30AM  
03:57AM  
Sep-22-21 10:32AM  
10:04AM  
08:36AM  
01:59AM  
Sep-21-21 10:32AM  
09:33AM  
08:30AM  
Sep-20-21 05:50PM  
10:41AM  
08:00AM  
07:30AM  
Sep-17-21 10:58AM  
09:09AM  
Sep-16-21 01:20PM  
07:30AM  
06:09AM  
Sep-15-21 03:08PM  
07:30AM  
Sep-14-21 05:50PM  
Sep-10-21 08:08AM  
06:01AM  
Sep-09-21 07:01PM  
04:20PM  
04:16PM  
01:18PM  
Sep-04-21 11:45AM  
Sep-02-21 04:17PM  
11:27AM  
Sep-01-21 05:50PM  
Aug-31-21 10:53AM  
Aug-30-21 11:14AM  
06:00AM  
Aug-29-21 06:37AM  
Aug-27-21 11:22AM  
Aug-26-21 05:50PM  
11:48AM  
06:00AM  
12:35AM  
Aug-25-21 06:39AM  
Aug-24-21 06:55AM  
Aug-20-21 06:01AM  
Aug-19-21 09:49AM  
Aug-18-21 09:48AM  
Aug-17-21 05:55PM  
01:14PM  
02:12AM  
Aug-16-21 06:13PM  
Aug-13-21 05:00PM  
12:30PM  
06:59AM  
Aug-12-21 05:32PM  
07:53AM  
Aug-11-21 06:16PM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01Option Exercise338.246,0052,031,1314,864Sep 03 04:08 PM
Sandrock AlfredHead of Research & DevelopmentJun 07Sale440.007,6723,375,68010,169Jun 09 07:05 PM
Guindo ChirfiHead of Glob Prod Strat & ComJun 07Sale440.003,0871,358,2802,919Jun 09 07:04 PM
Posner Brian SDirectorJun 04Sale274.1736098,7017,400Jun 07 07:02 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.004,454019,715Feb 17 05:01 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0016,289060,194Feb 17 05:03 PM
Kramer RobinSVP, Chief Accounting OfficerFeb 12Option Exercise0.003330706Feb 17 04:59 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.003,15606,946Feb 17 04:58 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.002,92309,288Feb 17 04:56 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,57304,765Feb 17 04:54 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.004,355043,509Feb 17 04:52 PM
Mantas Jesus BDirectorFeb 09Buy267.00898239,7662,943Feb 10 04:31 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00740395Dec 07 09:08 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0048104,004Dec 03 05:41 PM
Vounatsos MichelChief Executive OfficerNov 30Buy241.313,100748,04734,810Dec 01 04:57 PM
Sandrock AlfredEVP, Research & DevelopmentNov 04Sale350.001,500525,00013,066Nov 06 09:39 PM